Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, shares the results of a trial which investigated the tolerability and efficacy of zanubrutinib in patients with B-cell malignancies who were intolerant to acalabrutinib. Overall, it was shown that zanubrutinib was well tolerated by the patient population, with majority of patients not experiencing the side effects that they experienced with acalabrutinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.